Kazuyoshi Ohkawa - Concepedia

Author

Kazuyoshi Ohkawa

Also Known As

K OHKAWA, K Ohkawa, K. Ohkawa, KAZUYOSHI OHKAWA, Kazuyoshi OHKAWA, Kazuyoshi Ohkawa, Kazuyoshi Ohkawa*, Ohkawa Kazuyoshi

288

Publications

4.3K

Citations

H-Index

115

Concepts

All Affiliations

The University of Osaka Osaka International Cancer Institute Osaka National Hospital Ikeda Municipal Hospital Osaka Police Hospital

About

Kazuyoshi Ohkawa is an author at The University of Osaka specializing in medicine, pathology, and immunology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	22	35	1.6K
2	Health Sciences	9	9	589
3	Engineering	2	2	33
4	Language Studies	1	1	19
5	Public Health	1	1	45

Kazuyoshi Ohkawa

Publications

3.9K

Citations

H-Index

Page 1

	Year	Citations
Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma B. Sangro, Stephen L. Chan, Robin Kate Kelley, Annals of Oncology	2024	254
Clinical Practice Guidelines for Hepatocellular Carcinoma: The Japan Society of Hepatology 2021 version (5th JSH‐HCC Guidelines) Kiyoshi Hasegawa, Nobuyuki Takemura, Tatsuya Yamashita, Hepatology Research PathologyCancer RegistrationClinical Practice GuidelinesHepatic DisordersOncology	2023	235
Expression of vascular permeability factor/vascular endothelial growth factor in human hepatocellular carcinoma. Kazuhiro Suzuki, Norio Hayashi, Yoshiyuki Miyamoto, PubMed Human Hepatocellular CarcinomaOligonucleotide PrimersPathologyTumor BiologyVascular Permeability	1996	217
Multiomics identifies the link between intratumor steatosis and the exhausted tumor immune microenvironment in hepatocellular carcinoma Hiroki Murai, Takahiro Kodama, Kazuki Maesaka, Hepatology	2022	163
Mcl-1 and Bcl-xL Cooperatively Maintain Integrity of Hepatocytes in Developing and Adult Murine Liver† Hayato Hikita, Tetsuo Takehara, Satoshi Shimizu, Hepatology	2009	125
Hammerhead Ribozyme-Mediated Inhibition of Telomerase Activity in Extracts of Human Hepatocellular Carcinoma Cells Yoshiyuki Kanazawa, Kazuyoshi Ohkawa, Keiji Ueda, Biochemical and Biophysical Research Communications Hammerhead Ribozyme-mediated InhibitionOncogenic AgentMedicineTelomerase ActivityAnti-cancer Agent	1996	93
Effectiveness of Etoposide and Cisplatin vs Irinotecan and Cisplatin Therapy for Patients With Advanced Neuroendocrine Carcinoma of the Digestive System Chigusa Morizane, Nozomu Machida, Yoshitaka Honma, JAMA Oncology	2022	85
Anticancer Chemotherapy Inhibits MHC Class I–Related Chain A Ectodomain Shedding by Downregulating ADAM10 Expression in Hepatocellular Carcinoma Keisuke Kohga, Tetsuo Takehara, Tomohide Tatsumi, Cancer Research	2009	81
Interleukin-6 Is a Circulating Prognostic Biomarker for Hepatocellular Carcinoma Patients Treated with Combined Immunotherapy Yuta Myojin, Takahiro Kodama, Ryotaro Sakamori, Cancers	2022	80
Natural killer cell and hepatic cell interaction via NKG2A leads to dendritic cell‐mediated induction of CD4<sup>+</sup> CD25<sup>+</sup> T cells with PD‐1‐dependent regulatory activities Masahisa Jinushi, Tetsuo Takehara, Tomohide Tatsumi, Immunology Dendritic CellT-regulatory CellImmunologyImmune RegulationPathology	2006	79

Page 1